From Our 2007 Archives

Duchenne's Muscular Dystrophy Advance

Drug May Partially Correct Deadly Form of Muscular Dystrophy

By Daniel J. DeNoon
WebMD Health News

Reviewed By Louise Chang, MD

Dec. 27, 2007 -- An "antisense" compound may partially correct the genetic defect that causes deadly Duchenne's muscular dystrophy.

Researchers are not calling the finding a breakthrough, but they are cautiously optimistic that the approach may one day lead to a treatment that extends the lives of people afflicted with the always-fatal disease.

Duchenne's muscular dystrophy is a genetic disease seen in one in 3,500 baby boys. The boy's muscles get weaker and weaker, landing them in wheelchairs by their twelfth birthday. Their hearts and lungs also weaken, and the brain may be affected.

Most of these boys die in early childhood; with steroid treatment and breathing aids, their life span can be as long as 25 to 35 years. Nothing, however, prevents eventual death.

Now there's a small glimmer of hope. Scientists now know the specific genetic mutation that causes Duchenne's muscular dystrophy. That mutation causes a "misreading" of the gene that encodes dystrophin, a substance crucial for muscle cell survival.

In the test tube, a compound called an antisense oligonucleotide partially corrects this genetic misreading. It seems to work in animals. Might it work in humans?

Judith C. van Deutekom, PhD, of Netherlands' Leiden University, and colleagues tested the treatment, called PRO051, in four 10- to 13-year-old boys with Duchenne's muscular dystrophy. They'd all been confined to wheelchairs since ages 7 to 11.

Each boy got a single treatment -- four injections -- in a leg muscle. The idea wasn't to cure the boys, but to make sure nothing bad happened and to see whether the genetic correction works in humans.

The answer: Nobody got hurt by the treatment. And at the site of the injections, there were signs of dystrophin production.

On the downside, there was evidence that the disease in these young boys may have already advanced too far for an eventual treatment to be much help. Future clinical trials may require even younger patients.

The treatment, van Deutekom and colleagues cautiously conclude, "may be a potential approach to restoring dystrophin synthesis in the muscles of patients with Duchenne's muscular dystrophy."

The researchers report their findings in the Dec. 27 issue of TheNew England Journal of Medicine.

SOURCES: van Deutekom, J.C. The England Journal of Medicine, Dec. 27, 2007; vol 357: pp 2677-2686.

© 2007 WebMD Inc. All rights reserved.